Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8793979 | Ophthalmology | 2018 | 7 Pages |
Abstract
These analyses from real-world data indicate that anti-VEGF intravitreous injections are associated with a small but statistically significant decrease in IOP over time. A proportion of patients, on average 2.6%, experienced a sustained clinically significant IOP rise with these drugs overall compared with 1.5% in the fellow untreated eyes. However, such an increase was not seen with aflibercept.
Keywords
Intelligent Research in SightDMEGLMIVANVEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMDAMDCATTiOpDiabetic macular edemaBRAVOage-related macular degenerationDiabetic Retinopathy Clinical Research NetworkIrisVascular endothelial growth factorVascular Endothelial Growth Factor (VEGF)Intraocular pressureAnchorMarinaGeneralized linear modelViewCruiseCopernicusGalileo
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
Elizabeth A. MD, Kevin M. MS, Cynthia G. MD, Catherine N. PhD, Flora MD, Mathew W. MD, PhD,